Clinical Trial

Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents

Study acronym: B-NHL
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-04.
Trial Details
NCT Number NCT07168980
Lead Sponsor Children's Cancer Group, China
Collaborators: Shanghai Children's Medical Center, Nanjing Children's Hospital, Children's Hospital of Soochow University, West China Second University Hospital, Qilu Hospital of Shandong University, Tianjin Medical University Cancer Institute and Hospital, Xiangya Hospital of Central South University, Wuhan TongJi Hospital
Conditions Mature B-cell Non-Hodgkin Lymphoma
Enrollment 87 participants
Start Date 2025-07-01
Primary Completion 2030-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-04